Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years and Older.
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years and Older.
Sensenonics股價上漲，因爲該公司宣佈獲得FDA批准，推出其新一代Eversense 365持續血糖監測（CGM）系統，適用於18歲及以上的1型和2型糖尿病患者。
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years and Older.
Sensenonics股價上漲，因爲該公司宣佈獲得FDA批准，推出其新一代Eversense 365持續血糖監測（CGM）系統，適用於18歲及以上的1型和2型糖尿病患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。